Allergy Thera. Share News (AGY)

UK shareholder meetings calendar - next 7 days

Allergy Therapeutics forecasts revenue drop but trials going well

(Alliance News) - Allergy Therapeutics PLC on Wednesday said revenue decreased in its latest half year, and expects to require further funding soon.

TRADING UPDATES: Alliance Pharma appoints chair; FireAngel sales down

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Allergy Therapeutics resumes trading on AIM; annual revenue plunges

(Alliance News) - Allergy Therapeutics PLC on Tuesday resumed trading on AIM after the release of its annual results.

IN BRIEF: Allergy Therapeutics amends facility, plans warrant issue

Allergy Therapeutics PLC - Sussex-based biotechnology company specialising in allergy vaccines - Shares rise as firm enters amendment to the facility agreement it reached in early April with SkyGem Acquisition Ltd and Southern Fox Investments Ltd. Deal provides Allergy Therapeutics with a GBP40 million secured loan facility of which GBP32.5 million is uncommitted. Facility is available to drawdown between January 15 and the same day in 2026, with interest payable semi-annually at 12% per year and a January 15, 2027 repayment date.

EARNINGS AND TRADING: Redx full year revenue tumbles; loss widens

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

Allergy Therapeutics shares jump as hails grass allergy jab data

(Alliance News) - Allergy Therapeutics PLC on Wednesday said that phase-3 trials of its grass allergy injection yielded positive results, moving the product closer to market entry.

AIM WINNERS & LOSERS: Impellam climbs on GBP483 million takeover offer

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Allergy Therapeutics says allergy therapy trial meets primary endpoint

(Alliance News) - Allergy Therapeutics PLC on Tuesday said that a trial evaluating the efficacy of its subcutaneous allergen-specific immunotherapy candidate has met its primary endpoint.

AIM WINNERS & LOSERS: Renalytix revenue halves; DP Poland trades well

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

IN BRIEF: Allergy Therapeutics extends cash runway until end of 2023

Allergy Therapeutics PLC - West Sussex, England-based commercial biotechnology company - Says it continued to work on initiatives to improve cost control and manage working capital alongside trading broadly in line with expectations for the current financial year to date. Says it has extended its cash runway and anticipates to require additional funding by the end of December. Further, says discussions with some major shareholders regarding a subscription and open offer announced in October have progressed. Says that the pivotal phase 3 grass G306 modified allergen tyrosine adsorbed monophosphoryl lipid A trial remains on track to report interim results this month. Via G306, the company aims to release an immunotherapy for grass allergy.

ZQ makes mandatory offer for Allergy Therapeutics as holding hits 60%

(Alliance News) - ZQ Capital Management Ltd on Monday announced a mandatory takeover offer for Allergy Therapeutics PLC, as required under UK takeover rules, but it said the offer won't be accepted by the Allergy's second largest shareholder and so won't succeed.

IN BRIEF: Allergy Therapeutics raises GBP40.8 million in fundraise

Allergy Therapeutics PLC - West Sussex, England-based commercial biotechnology company - Says that it has conditionally raised total gross proceeds of approximately GBP40.8 million through an equity financing, which was announced on April 6. Proceeds of the equity financing will be used to repay amounts owed under the loan facility agreement.

EARNINGS: Safestyle suffers amid "difficult" trading conditions

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: